Donna D. Catamero

Donna D. Catamero,

ANP-BC, OCN, CCRC

Donna D. Catamero,

ANP-BC, OCN, CCRC

Associate Director, Myeloma Research, Icahn School of Medicine at Mount Sinai

Donna D. Catamero

Donna D. Catamero,

ANP-BC, OCN, CCRC

Associate Director, Myeloma Research, Icahn School of Medicine at Mount Sinai

Donna Catamero received a Bachelor of Science in Nursing from Simmons College in 2002 and her Master of Science in Nursing from New York University in 2010. For 20 years, Donna has been involved in clinical research. She worked as a nurse practitioner in the Multiple Myeloma Program at New York University Langone Medical Center in New York City and later at Mount Sinai until 2018. Then, she spent two years in industry working as Scientific Director of Medical Affairs in multiple myeloma, where she developed expertise in both BCMA research and education development for healthcare providers. She is now back at Mount Sinai, where she serves as Associate Director of Myeloma Research. In this position, she oversees clinical research projects and develops standards of care for professional practice. In addition to her clinical and administrative roles, Donna is adjunct faculty in the Mount Sinai Phillips School of Nursing.

Donna is an active author, presenter, and educator including co-authoring “On the Horizon,” the concluding chapter in Multiple Myeloma: A Textbook for Nurses (3rd ed.) addressing the rapidly changing landscape of myeloma. Having worked on the frontlines during the initial COVID-19 surge in New York City, among her many publications was a timely article on “Considerations of COVID-19–Specific Myeloma Guidelines in New York City.”

She recently presented for the JADPRO Roundtable and for Myeloma Australia. Donna is a member of the International Myeloma Foundation Nurse Leadership Board since 2014. She has served as a chairperson for roundtables and advisory boards and presented at International Myeloma Foundation patient and family seminars.

Donna's Shared Resources

Increased Infection Risk With Bispecific Antibodies in Multiple Myeloma

Bispecific antibodies, a novel immunotherapy for multiple myeloma, create immune synapses between T-cell marker CD3 and malignant cell markers like B-cell maturation antigen (BCMA), FcRH5, and GPRC5D, effectively depleting plasma...
CURATED BY:
Donna D. Catamero,
ANP-BC, OCN, CCRC

Limiting Early Mortality: Managing Patients With Newly Diagnosed Multiple Myeloma

Multiple myeloma (MM) survival continues to improve, but population-level data indicate that early mortality remains a substantial barrier to advances in MM outcomes. Recommendations are made for management may minimize...
CURATED BY:
Donna D. Catamero,
ANP-BC, OCN, CCRC

Provided by an unrestricted grant from

Provided by an unrestricted grant from

Share